US Clinical Practice Experience with Eculizumab in Myasthenia Gravis: Acute Clinical Events and Healthcare Resource Utilization.

Drugs Real World Outcomes · 2024 · PMC11589080 · PMID 39470958

Europe PMC DOI

hedged sentence

0.0558

closest p · 1.1× alpha

0.0558

boldest claim

The sentences

did not reach statistical significancep = 0.0558so close (0.05 < p ≤ 0.1)

The mean annualized rate of exacerbation-related ED visits decreased by four-fifths after eculizumab initiation, from 0.054 PPPY before eculizumab initiation to 0.012 PPPY during eculizumab treatment; however, the difference did not reach statistical significance ( p = 0.0558; Fig. 1 a).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.